1-13 of 13
Joyce F. Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Available to Purchase
Jung-Min Lee, Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John, Chirag A. Shah, Koji Matsuo, Jean Siedel, David S. Miller, Elizabeth E. Hopp, Andrea O’Shea, John K. Chan, Leslie S. Bradford, Christopher B. Morse, Christa I. Nagel, Kerry J. Rodabaugh, Elise C. Kohn, Kathleen N. Moore, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12): 2370–2378.
https://doi.org/10.1158/1078-0432.CCR-24-3877
Published: 13 June 2025
View articletitled, Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Open the PDF for Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Open Access
Ryan B. Corcoran, Khanh T. Do, Jeong E. Kim, James M. Cleary, Aparna R. Parikh, Oladapo O. Yeku, Niya Xiong, Colin D. Weekes, Jennifer Veneris, Leanne G. Ahronian, Gianluca Mauri, Jun Tian, Bryanna L. Norden, Alexa G. Michel, Emily E. Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J. Fetter, Joan S. Brugge, Helen Chen, Naoko Takebe, Richard T. Penson, Dejan Juric, Keith T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, Ursula A. Matulonis, Joyce F. Liu, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1739–1749.
https://doi.org/10.1158/1078-0432.CCR-23-3135
Published: 01 May 2024
View articletitled, Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Open the PDF for Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)

Free
Rebecca L. Porter, Sandy Elias, Niya Xiong, Madeline Polak, Kayla Fahey, Nabihah Tayob, Courtney Qi, Carina Feeney, Swati Narayan, Jennifer Curtis, Susana Campos, Carolyn Krasner, Elizabeth Lee, Elizabeth Stover, Alexi A. Wright, Joyce F. Liu, Ursula A. Matulonis, Panagiotis Konstantinopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5_Supplement): B013.
https://doi.org/10.1158/1557-3265.ENDO24-B013
Published: 01 March 2024
View articletitled, Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)
Journal Articles

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Open Access
Jung-Min Lee, Richard G. Moore, Sharad Ghamande, Min S. Park, John P. Diaz, Julia Chapman, James Kendrick, Brian M. Slomovitz, Krishnansu S. Tewari, Elizabeth S. Lowe, Tsveta Milenkova, Sanjeev Kumar, Mike Dymond, Jessica Brown, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4186–4193.
https://doi.org/10.1158/1078-0432.CCR-21-1733
Published: 03 October 2022
View articletitled, Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Open the PDF for Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial in another window
Includes: Supplementary data
Journal Articles

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

Open Access
Min Liu, Nabihah Tayob, Livius Penter, MacLean Sellars, Anna Tarren, Vipheaviny Chea, Isabel Carulli, Teddy Huang, Shuqiang Li, Su-Chun Cheng, Phuong Le, Laura Frackiewicz, Julia Fasse, Courtney Qi, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Kenneth J. Livak, Donna Neuberg, Guanglan Zhang, Ursula A. Matulonis, Catherine J. Wu, Derin B. Keskin, Panagiotis A. Konstantinopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3356–3366.
https://doi.org/10.1158/1078-0432.CCR-21-2834
Published: 02 August 2022
View articletitled, Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Open the PDF for Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Open Access
Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2020–2029.
https://doi.org/10.1158/1078-0432.CCR-21-3656
Published: 13 May 2022
View articletitled, Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Open the PDF for Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial in another window
Includes: Supplementary data
Journal Articles

Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS

Free
Sarah J. Hill, Brennan Decker, Emma A. Roberts, Chunyu Yang, Neil S. Horowitz, Michael G. Muto, Michael J. Worley, Jr., Colleen M. Feltmate, Marisa R. Nucci, Elizabeth M. Swisher, Ryuji Morizane, Bose Kochupurakkal, Khanh T. Do, Panagiotis Konstantinopoulos, Joyce F. Liu, Joseph V. Bonventre, Ursula A. Matulonis, Geoffrey I. Shapiro, Ross S. Berkowitz, Christopher P. Crum, Alan D. D'Andrea
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): AP10.
https://doi.org/10.1158/1557-3265.OVCASYMP18-AP10
Published: 15 November 2019
View articletitled, Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS
Journal Articles

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Free
Kalindi Parmar, Bose S. Kochupurakkal, Jean-Bernard Lazaro, Zhigang C. Wang, Sangeetha Palakurthi, Paul T. Kirschmeier, Chunyu Yang, Larissa A. Sambel, Anniina Färkkilä, Elizaveta Reznichenko, Hunter D. Reavis, Connor E. Dunn, Lee Zou, Khanh T. Do, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu, Alan D. D'Andrea, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6127–6140.
https://doi.org/10.1158/1078-0432.CCR-19-0448
Published: 15 October 2019
View articletitled, The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Open the PDF for The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

Free
Jessica J. Tao, Nicholas A. Cangemi, Vicky Makker, Karen A. Cadoo, Joyce F. Liu, Drew W. Rasco, Willis H. Navarro, Christopher M. Haqq, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5458–5465.
https://doi.org/10.1158/1078-0432.CCR-19-1065
Published: 13 September 2019
View articletitled, First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer

Free
Douglass W. Tucker, Christopher R. Getchell, Eric T. McCarthy, Anders W. Ohman, Naoko Sasamoto, Shuyun Xu, Joo Yeon Ko, Mamta Gupta, Amy Shafrir, Jamie E. Medina, Jonathan J. Lee, Lauren A. MacDonald, Ammara Malik, Kathleen T Hasselblatt, Wenjing Li, Hong Zhang, Samuel J. Kaplan, George F. Murphy, Michelle S. Hirsch, Joyce F. Liu, Ursula A. Matulonis, Kathryn L. Terry, Christine G. Lian, Daniela M. Dinulescu
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (6): 1389–1401.
https://doi.org/10.1158/1078-0432.CCR-17-1958
Published: 14 March 2018
View articletitled, Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Open the PDF for Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER

Free
Zhigang C. Wang, Nicolai Juul Birkbak, William T. Barry, Thomas M. Roberts, Eric P. Winer, J Dirk Iglehart, Ursula A. Matulonis, S. Percy Ivy, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-112.
https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-112
Published: 31 May 2017
View articletitled, Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER
Journal Articles

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Free
Joyce F. Liu, Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Elena Ivanova, Wei Huang, Ioannis K. Zervantonakis, Laura M. Selfors, Yiping Shen, Colin C. Pritchard, Mei Zheng, Vilmos Adleff, Eniko Papp, Huiying Piao, Marian Novak, Susan Fotheringham, Gerburg M. Wulf, Jessie English, Paul T. Kirschmeier, Victor E. Velculescu, Cloud Paweletz, Gordon B. Mills, David M. Livingston, Joan S. Brugge, Ursula A. Matulonis, Ronny Drapkin
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (5): 1263–1273.
https://doi.org/10.1158/1078-0432.CCR-16-1237
Published: 28 February 2017
View articletitled, Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Open the PDF for Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics in another window
Includes: Supplementary data
Journal Articles

Abstract PR02: Cyclin E1 deregulation occurs early during fallopian tube tumorigenesis and promotes secretory cell transformation

Free
Alison M. Karst, Paul M. Jones, Natalie Vena, Azra H. Ligon, Joyce F. Liu, Michelle S. Hirsch, Dariush Etemadmoghadam, David D. Bowtell, Ronny Drapkin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): PR02.
https://doi.org/10.1158/1078-0432.OVCA13-PR02
Published: 13 May 2014
View articletitled, Abstract PR02: Cyclin E1 deregulation occurs early during fallopian tube tumorigenesis and promotes secretory cell transformation